Nureca Ltd (NURECA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003462, "name": "Nureca", "stock_name": "Nureca", "full_name": "Nureca Ltd", "name_url": "stocks-analysis/nureca", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "289.30", "chg": 0.05, "chgp": "0.02%", "dir": 1, "prev_price": "289.25", "mcapval": "277.00 Cr", "mcap": "Micro Cap", "scripcode": 543264, "symbol": "NURECA", "ind_name": "Healthcare Services", "ind_code": 26, "indexname": "India SENSEX", "isin": "INE0DSF01015", "curr_date": "May 08", "curr_time": "", "bse_nse_vol": "12.94 k", "exc_status": "Active", "traded_date": "May 08, 2026", "traded_date_str": "2026 05 08", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nureca-1003462-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Nureca Ltd is Rated Sell by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-is-rated-sell-by-marketsmojo-3982704", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NurecaLtd_mojoScore_3982704.png", "date": "2026-05-09 10:10:36", "description": "Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Nureca Ltd Upgraded to Sell by MarketsMOJO on Technical Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-upgraded-to-sell-by-marketsmojo-on-technical-improvements-3965958", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3965958.png", "date": "2026-04-28 08:54:00", "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 27 Apr 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent challenges in its long-term fundamentals and valuation metrics. The upgrade is primarily driven by improvements in technical indicators, while financial trends and quality scores remain mixed, prompting a cautious stance among investors." }, { "title": "Nureca Ltd Downgraded to Strong Sell Amid Technical Weakness and Valuation Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-downgraded-to-strong-sell-amid-technical-weakness-and-valuation-concerns-3955379", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3955379.png", "date": "2026-04-21 08:45:08", "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 20 Apr 2026. This shift reflects deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamental trends despite recent positive quarterly financial results." }, { "title": "Nureca Ltd Investment Rating Upgraded to Sell on Technical and Financial Developments", "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-investment-rating-upgraded-to-sell-on-technical-and-financial-developments-3948644", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3948644.png", "date": "2026-04-16 08:42:31", "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent challenges in its fundamental financial metrics. The upgrade is driven primarily by improvements in technical indicators, while valuation and financial trends present a mixed picture for investors." }, { "title": "Nureca Ltd Gains 8.82%: 3 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-gains-882-3-key-factors-driving-the-weeks-volatility-3942587", "imagepath": "", "date": "2026-04-11 12:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>6 Apr:</strong> Valuation metrics signal expensive territory amid sector challenges</p>\n <p><strong>7 Apr:</strong> Formation of Death Cross indicates potential bearish trend</p>\n <p><strong>8 Apr:</strong> Mojo Grade downgraded to Strong Sell reflecting technical and fundamental weakness</p>\n <p><strong>10 Apr:</strong> Week closes at Rs.260.95, up 8.82% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.239.80</div></div>\n <div class=\"stat-item\"><div class=\"stat-label..." }, { "title": "Nureca Ltd Downgraded to Strong Sell Amid Bearish Technicals and Expensive Valuation", "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-downgraded-to-strong-sell-amid-bearish-technicals-and-expensive-valuation-3936617", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3936617.png", "date": "2026-04-08 08:26:52", "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 April 2026. This shift reflects a confluence of deteriorating technical indicators, an expensive valuation profile, weak financial trends, and subpar quality metrics. The downgrade comes despite the company’s recent positive quarterly results, underscoring growing concerns about its longer-term fundamentals and market positioning." }, { "title": "Nureca Ltd Forms Death Cross, Signalling Potential Bearish Trend", "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-forms-death-cross-signalling-potential-bearish-trend-3936130", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_dealthcross_3936130.png", "date": "2026-04-07 18:00:41", "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has recently formed a Death Cross, a technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook." }, { "title": "Nureca Ltd Valuation Shifts Signal Price Attractiveness Concerns Amid Sector Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-valuation-shifts-signal-price-attractiveness-concerns-amid-sector-challenges-3933721", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_valuationdot_3933721.png", "date": "2026-04-06 08:01:36", "description": "Nureca Ltd, a micro-cap player in the healthcare services sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. Despite a recent day gain of 5.87%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now exceed historical and peer averages, raising questions about its price attractiveness amid subdued returns and deteriorating profitability metrics." }, { "title": "Nureca Ltd is Rated Sell by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-is-rated-sell-by-marketsmojo-3933044", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3933044.png", "date": "2026-04-04 10:10:02", "description": "Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook." } ], "total": 263, "sid": "1003462", "stock_news_url": "https://www.marketsmojo.com/news/nureca-1003462" }, "announcements": [ { "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018", "datetime": "15-Apr-2026", "details": "Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants ) Regulations 2018 .", "source": "BSE" }, { "caption": "Closure of Trading Window", "datetime": "27-Mar-2026", "details": "Nureca Limited has informed the exchange regarding Trading Window Closure .", "source": "BSE" }, { "caption": "Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011", "datetime": "31-Jan-2026", "details": "The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saurabh Goyal Aryan Goyal Payal Goyal Smita Goyal & Nectar Biopharma Pvt Ltd", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Nureca Ltd has declared <strong>30%</strong> dividend, ex-date: 24 Feb 22", "dt": "2022-02-24", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

6 Apr: Valuation metrics signal expensive territory amid sector challenges

7 Apr: Formation of Death Cross indicates potential bearish trend

8 Apr: Mojo Grade downgraded to Strong Sell reflecting technical and fundamental weakness

10 Apr: Week closes at Rs.260.95, up 8.82% for the week

Week Open

Rs.239.80

Read full news article

Nureca Ltd Downgraded to Strong Sell Amid Bearish Technicals and Expensive Valuation

2026-04-08 08:26:52

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 April 2026. This shift reflects a confluence of deteriorating technical indicators, an expensive valuation profile, weak financial trends, and subpar quality metrics. The downgrade comes despite the company’s recent positive quarterly results, underscoring growing concerns about its longer-term fundamentals and market positioning.

Read full news article

Nureca Ltd Forms Death Cross, Signalling Potential Bearish Trend

2026-04-07 18:00:41

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has recently formed a Death Cross, a technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.

Read full news article

Nureca Ltd Valuation Shifts Signal Price Attractiveness Concerns Amid Sector Challenges

2026-04-06 08:01:36

Nureca Ltd, a micro-cap player in the healthcare services sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. Despite a recent day gain of 5.87%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now exceed historical and peer averages, raising questions about its price attractiveness amid subdued returns and deteriorating profitability metrics.

Read full news article

Nureca Ltd is Rated Sell by MarketsMOJO

2026-04-04 10:10:02

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article